Desai M A
Public Health Laboratory Service, Centre for Applied Microbiology and Research, Salisbury, Wiltshire, UK.
J Chem Technol Biotechnol. 1990;48(2):105-26. doi: 10.1002/jctb.280480202.
This review describes immunoaffinity purification as a tool for the process-scale isolation of high-value, therapeutic-grade biochemicals from complex media. To this end, practicalities of activation, antigen coupling and operation in anti-human IgG monoclonal antibody recovery have been studied using cyanogen-bromide activated Sepharose CL-4B and composite Macrosorb K4AX immobilised with polyclonal human IgG as a model for general immunoaffinity systems. The characteristics required of solid phases are discussed in the context of the efficient application of bioselective processes early in the purification sequences. The importance of the technique for isolating biologically active biomolecules for in-vivo administration has been discussed in the light of current, stringent regulatory requirements. Finally, the prospect of scale-up and automation of the technique has been evaluated.
本综述将免疫亲和纯化描述为一种从复杂介质中进行工艺规模分离高价值治疗级生化物质的工具。为此,以溴化氰活化的琼脂糖凝胶CL - 4B和固定有多克隆人IgG的复合大孔吸附剂K4AX作为通用免疫亲和系统的模型,研究了抗人IgG单克隆抗体回收中活化、抗原偶联及操作的实际情况。在纯化序列早期生物选择性过程的有效应用背景下,讨论了固相所需的特性。鉴于当前严格的监管要求,探讨了该技术在分离用于体内给药的生物活性生物分子方面的重要性。最后,评估了该技术放大和自动化的前景。